Form 4: Hims & Hers Health CFO Oluyemi Okupe Executes Stock Option Exercise and Sales

Chief Financial Officer Oluyemi Okupe of Hims & Hers Health, Inc. reports exercising stock options and selling Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On January 13, 2025, Oluyemi Okupe, the Chief Financial Officer of Hims & Hers Health, Inc., executed transactions involving the company's Class A Common Stock.
• Okupe exercised stock options to acquire 6,437 shares at a price of $5.01 per share.
• Concurrently, Okupe sold a total of 12,581 shares of Class A Common Stock in multiple transactions at weighted average prices ranging from $24.4151 to $24.5688.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 31, 2024.
• Following these transactions, Okupe directly owns 118,077 shares of Class A Common Stock and 426,174 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports transactions under a pre-existing plan. There's no indication of positive or negative implications for the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the existence of a 10b5-1 plan mitigates this concern.

Industry Context

Executive stock transactions are common and closely monitored, especially in publicly traded companies like Hims & Hers Health. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among executives at publicly traded companies to manage their stock holdings in a compliant manner.
• Comparing Okupe's transactions to those of other CFOs in similar-sized healthcare companies would provide further context, but that data is not available in this document.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, depending on market perception of insider sales.
• The transactions do not appear to directly impact employees, customers, suppliers, or creditors.

Key Dates